It has been reported that HCSI inhibits cholesterol metabolism by targeting the AMPK/SREBP1/FASN pathway and affects the tumor microenvironment, thus inhibiting the progression of hepatocellular carcinoma [16]. Here, SREBF1 is linked to hepatocellular carcinoma.